RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
Yiran Liang(Qilu Hospital of Shandong University), Qifeng Yang(Qilu Hospital of Shandong University), Fangzhou Ye(Qilu Hospital of Shandong University), Hanwen Zhang(Qilu Hospital of Shandong University), Ning Zhang(Qilu Hospital of Shandong University), Ying Liu(Qilu Hospital of Shandong University), Bing Chen(Shandong University), Yajie Wang(Capital Medical University), Xiaoyan Li(Qilu Hospital of Shandong University), Yaming Li(Qilu Hospital of Shandong University), Xiaojin Song(Qilu Hospital of Shandong University), Dan Luo(Qilu Hospital of Shandong University), Wenjing Zhao(Qilu Hospital of Shandong University), Lijuan Wang(People 's Hospital of Jilin Province), Tingting Ma(Qilu Hospital of Shandong University), Dianwen Han(Qilu Hospital of Shandong University)
Cited by 396
Related Papers
Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
|Seminars in Cancer Biology|2019|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer
|Molecular Therapy|2019|513
LncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA‐215
|Journal of Cellular Physiology|2018|301
Ultrasensitive single-cell proteomics workflow identifies >1000 protein groups per mammalian cell
|Chemical Science|2020|245